<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23468">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02022813</url>
  </required_header>
  <id_info>
    <org_study_id>CE 371-13</org_study_id>
    <nct_id>NCT02022813</nct_id>
  </id_info>
  <brief_title>Impact of Supplemental Parenteral Nutrition in ICU Patients on Metabolic, Inflammatory and Immune Responses</brief_title>
  <acronym>SPN2</acronym>
  <official_title>Impact of Supplemental Parenteral Nutrition (SPN) on Energy Balance, and Infection Rate in Intensive Care Patients: Underlying Metabolic, Inflammatory and Immune Mechanisms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Geneva, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Having previously demonstrated that supplemental parenteral nutrition to complete an
      insufficient enteral nutrition (EN) between D4 and D8 improves outcome after critical
      illness, by reducing infectious complications, the present trial aims at investigating the
      underlying carbohydrate and protein metabolism changes, as well as the immune and
      inflammatory modulations associated with this improvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrollment on day 3 of critically ill patients, without contraindication to EN, not
      achieving 60% of the ICU per protocol energy target.

      Intervention: Randomization to either continued pure EN, or from day 4 to supplemental PN to
      complete EN at target validated by indirect calorimetry.

      Measurements: Indirect calorimetry on Days 3, 4, 9 (twice). Primary endpoints = glucose and
      leucine metabolism On days 4 and 9-10: isotopic investigation of glucose metabolism, and
      immune and inflammatory responses// Day 9-10: isotopic investigation of protein (leucine)
      metabolism Secondary endpoints: Insulin requirements, area under the curve (AUC) of blood
      Glucose, infections after day 9, overall complications, length of mechanical ventilation, of
      ICU and hospital stay.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Glucose and Leucine turnover</measure>
    <time_frame>10 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>On D04:Infusion after priming of 6.6 2H2 glucose and NaH13CO3 On Day 09-10: Infusion after priming of NaH13CO3 and of L-[1-13C]-Leucine + repeat of the glucose sequence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune and inflammatory impact of optimized target feeding</measure>
    <time_frame>10 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>lymphocyte phenotypes: lymphocyte subpopulations (frequency), level of activation (CD69), memory markers, effectors, regulators
Cluster differentiation CD4, CD8, and natural killer (NK) phenotypes
Cell inflammatory response (WBA and PBMC) on D4 and D10±1: IL-2, TNF-α, interleukine-6 (IL-6), IL-1, TGF, IL-10, in culture for 24 to 48h ex vivo and post stimulation by memory mix and mitogens.
Serological inflammatory response (WBA and PBMC) on D4 and D10+1: TNF-α , IL-6, C-reactive protein (CRP): ex vivo with ELISA Nosocomial infections after day 8</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Global outcome</measure>
    <time_frame>28 days / 90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Overall complications and organ failures, length of mechanical ventilation, length of ICU and hospital stay.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Enteral nutrition only</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Enteral nutrition to be progressed as soon as possible to energy target measured on day 3, and verified on day 4, using the usual facilitators (prokinetics)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplemental parenteral nutrition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Addition of supplemental parenteral nutrition to complete the gap between energy delivered by enteral feeding and energy target measured on day 4.
Aim: 100% of this target, and not exceeding it, no catch up for energy deficit accumulated before day 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Supplemental parenteral nutrition (SPN)</intervention_name>
    <description>The amount of energy delivered by SPN will depend on the indirect calorimetry measurement and actual enteral feed delivery. SPN will be reduced with progressing EN</description>
    <arm_group_label>Supplemental parenteral nutrition</arm_group_label>
    <other_name>Standard industrial PN solutions</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  estimated duration of ICU stay &gt; 5 days,

          -  estimated survival &gt; 7 days,

          -  absence of contraindication to EN

          -  need for mechanical ventilation

          -  informed consent obtained from patients, close relative, or referring physician

        Exclusion Criteria:

          -  refusal of the patient or of the next of kin

          -  age &lt; 18 years

          -  non-functional digestive tract (short bowel, persistent ileus, proximal intestinal
             fistula high rate  &gt; 1.5 litres/day)

          -  already receiving PN before Day 3

          -  absence of a central venous catheter

          -  women who are pregnant (pregnancy test).

          -  Admission after cardiac arrest, or severe brain injury
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mette M Berger, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUV, Lausanne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mette M Berger, MD PhD</last_name>
    <phone>+41 21 31 42 095</phone>
    <email>Mette.Berger@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claude Pichard, MD PhD</last_name>
    <phone>+41 22 372 93 45</phone>
    <email>Claude.Pichard@unige.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nutrition Unit, Geneva University Hospital</name>
      <address>
        <city>Geneva</city>
        <state>GE</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claude Pichard, MD PhD</last_name>
      <phone>+41 22 372 93 75</phone>
      <email>Claude.Pichard@unige.ch</email>
    </contact>
    <investigator>
      <last_name>Claude Pichard, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service of Adult Intensive Care - CHUV</name>
      <address>
        <city>Lausanne</city>
        <state>VD</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mette M Berger, MD PhD</last_name>
      <phone>+41 21 31 42 095</phone>
      <email>Mette.Berger@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Luc Tappy, Md PhD</last_name>
      <phone>+41 21 692 55 41</phone>
      <email>Luc.Tappy@unil.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Mette M Berger, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francois Spertini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Physiology Department, Unil</name>
      <address>
        <city>Lausanne</city>
        <zip>1005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Heidegger CP, Berger MM, Graf S, Zingg W, Darmon P, Costanza MC, Thibault R, Pichard C. Optimisation of energy provision with supplemental parenteral nutrition in critically ill patients: a randomised controlled clinical trial. Lancet. 2013 Feb 2;381(9864):385-93. doi: 10.1016/S0140-6736(12)61351-8. Epub 2012 Dec 3.</citation>
    <PMID>23218813</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 22, 2013</lastchanged_date>
  <firstreceived_date>November 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Mette M Berger</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>Energy requirements, Glucose turnover, Protein turnover</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
